The Kashfi Lab explores the treatment and prevention of inflammatory-based diseases, including cancers of the colon, pancreas, and ER-negative breast, using novel compounds such as dual nitric oxide and hydrogen sulfide-donating NSAIDs (NOSH-NSAIDs) developed in the lab. Dr. Kashfi’s research also addresses the prevention of familial adenomatous polyposis with gastrointestinally safe sulindac and the role of nitric oxide in type 2 diabetes.
Visit Dr. Kashfi’s PubMed and ORCiD pages for research activity and publications.